Dasatinib
About
Therapy type: Targeted therapy
Therapy strategy: BCR-ABL inhibition
Mappings
NCI Thesaurus: Dasatinib (ncit:C38713)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Chronic Myelogenous Leukemia | Dasatinib | |
| Sensitivity (+) | BCR::ABL1 | Acute Lymphoid Leukemia | Dasatinib |